Review of Ocular Drug Delivery

Abstract

Successful treatment of eye diseases requires effective concentration of drug at the eye for sufficient period of time. Conventional ocular drug delivery including eye drops, systemic administration, ophthalmic ointments, is no longer sufficient to combat ocular diseases. This article reviews the constraints with conventional ocular therapy, and explores various novel approaches, to improve the ocular bioavailability of drugs to the anterior chamber of the eye.

Ciprofloxacin as Ocular Liposomal Hydrogel

“…Poor bioavailability of drugs from conventional ocular dosage forms is mainly due to the precorneal loss factors, which include tear dynamics, insufficient residence time in the conjunctival sac and non-productive absorption (1)(2)(3).…”

In vitro dissolution/release methods for mucosal delivery systems

“…This setup is widely employed for in vitro drug release testing from ocular inserts [50] and contact lenses [51]. Sometimes is also used in case of semisolid dosage forms [6], microparticles for nasal application [52] and thermosensitive gels for buccal application [53].…”

Basic Research and Clinical Application of Drug Delivery Systems for the Treatment of Age-Related Macular Degeneration

“…In the recent past years review articles have focused on drug delivery to the eye (Acharya & Young 2004;Andreoli & Miller, 2007;Barar, Javadzadeh & Omidi, 2008;Barocas & Balachandran 2008;Bekeredjian, Katus & Kuecherer, 2006;Booth et al 2007;Del Amo & Urtti, 2008;Gaudana et al 2009;Hoffman, 2008;Hsu, 2007;Lee & Robinson, 2009;Lemley & Han, 2007;Liu & Regillo, 2004;Mitra, 2009;Novack, 2009;Sultana et al, 2006). The aim of this chapter is to emphasize recent advances in ocular drug delivery techniques most suitable for AMD.…”